Nature Reviews Drug Discovery

Top Research Topics at Nature Reviews Drug Discovery?

Nature Reviews Drug Discovery aims to foster the development of research in Pharmacology, Drug discovery, MEDLINE, Internal medicine and Drug development. More specifically, the research on Pharmacology in the journal is related to Drug. Issues in Drug discovery were discussed, taking into consideration concepts from other disciplines like Cancer, Cancer research and Computational biology.

The work on MEDLINE tackled in Nature Reviews Drug Discovery brings together disciplines like Text mining and Intensive care medicine. Many of the studies tackled connect Intensive care medicine with a similar field of study like Clinical trial. The journal explores topics in Internal medicine which can be helpful for research in disciplines like Endocrinology and Oncology.

• Pharmacology (15.77%)
• Drug discovery (15.35%)
• MEDLINE (12.56%)

What are the most cited papers published in the journal?

• Recent advances with liposomes as pharmaceutical carriers. (3799 citations)
• Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? (3336 citations)
• Nanoparticle therapeutics: an emerging treatment modality for cancer (3334 citations)

Research areas of the most cited articles at Nature Reviews Drug Discovery:

The published articles aim to foster the development of research in Drug discovery, Pharmacology, Bioinformatics, Cancer and Computational biology. The works on Drug discovery tackled in the journal papers bring together disciplines like Nanotechnology, Biotechnology, Drug development, Risk analysis (engineering) and Neuroscience. Pharmacology research is the primary subject tackled in the published articles with a focus in Drug.

What topics the last edition of the journal is best known for?

• Internal medicine
• Gene
• Cancer

The previous edition focused in particular on these issues:

Nature Reviews Drug Discovery generally zeroes in on subjects such as MEDLINE, Text mining, Computational biology, Cancer research and Bioinformatics. The journal holds forums on MEDLINE that merges themes from other disciplines such as Internal medicine, Clinical trial, Oncology, Family medicine and Intensive care medicine. The journal connects the study in Clinical trial with the closely related area of Disease.

Cancer research research featured in the journal incorporates concerns from various other topics such as Cancer and Kinase. Nature Reviews Drug Discovery links adjacent topics like Cancer with Drug discovery. Discussions in Nature Reviews Drug Discovery are anchored in the subject of Drug discovery and the similar topic of Drug development.

The most cited articles from the last journal are:

• Engineering precision nanoparticles for drug delivery (250 citations)
• Natural products in drug discovery: advances and opportunities. (160 citations)
• Organs-on-chips: into the next decade (90 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Nature Reviews Drug Discovery (based on the number of publications) are:

• Sarah Crunkhorn (480 papers) published 53 papers at the last edition, 10 more than at the previous edition,
• Asher Mullard (385 papers) published 54 papers at the last edition, 8 more than at the previous edition,
• Charlotte Harrison (244 papers) absent at the last edition,
• Peter Kirkpatrick (214 papers) absent at the last edition,
• Alexandra Flemming (124 papers) published 1 paper at the last edition, 2 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Nature Reviews Drug Discovery (based on the number of publications) are:

• Harvard University (75 papers) published 6 papers at the last edition, 5 more than at the previous edition,
• National Institutes of Health (58 papers) published 3 papers at the last edition, 1 less than at the previous edition,
• GlaxoSmithKline (56 papers) published 3 papers at the last edition, 1 more than at the previous edition,
• AstraZeneca (55 papers) published 5 papers at the last edition, 3 more than at the previous edition,
• Pfizer (52 papers) published 2 papers at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 79.92% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 29.17% were posted by at least one author from the top 10 institutions publishing in the journal. Another 22.92% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 27.08% of all publications and 20.83% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Paths in Clinical Research

For those interested in furthering their career in clinical research and possibly contributing to the topics and areas discussed in Nature Reviews Drug Discovery, becoming a Nurse Practitioner could be a promising path. Nurse Practitioners are registered nurses who have completed additional training and education to handle the responsibilities of a healthcare provider. As a Nurse Practitioner, one could work on front-line care, including diagnosis and management of acute and chronic illnesses, as well as contribute to drug discovery and development process through their unique clinical insight. If you live in Washington and interested in this career path, you can follow [this guide](https://research.com/careers/how-to-become-a-nurse-practitioner-in-washington) on how to become a nurse practitioner in Washington. This guide provides detailed career and education information, job outlook, salary expectations, and detailed steps to becoming a Nurse Practitioner. Moreover, Nurse Practitioners have the opportunity to choose a specialty such as Family Medicine, Adult-Gerontology, or Pediatrics. Whichever specialty one chooses, becoming a Nurse Practitioner could open doors to contributing to clinical research and drug discovery, and play a role in shaping the future of healthcare.